AI in Personalized Medicine Market Forecasts to 2034 – Global Analysis By Component (Software, Hardware, and Services), Technology Therapeutic Area, Data Type, Application, End User and By Geography
According to Stratistics MRC, the Global AI in Personalized Medicine Market is accounted for $2.8 billion in 2026 and is expected to reach $57.3 billion by 2034, growing at a CAGR of 38.2% during the forecast period. AI in Personalized Medicine involves leveraging machine learning and data-driven techniques to customize healthcare for each patient. By examining extensive genetic, clinical, and lifestyle information, AI systems can forecast disease likelihood, recommend optimal therapies, and improve treatment effectiveness. This approach advances precision medicine by enhancing diagnostic precision, minimizing side effects, and assisting healthcare providers in delivering individualized care. Ultimately, it empowers more accurate, efficient, and patient-focused medical decision-making.
Market Dynamics:
Driver:
Exponential growth in genomic and multi-omics data
The exponential growth in genomic and multi-omics data is a primary driver for AI integration. As sequencing costs decline, the volume of genetic information available for analysis has surged. AI algorithms, particularly machine learning, are uniquely capable of processing these vast, complex datasets to identify disease markers and predict drug responses. This capability enables the shift from traditional trial-and-error medicine to precise therapeutic interventions. Furthermore, the increasing demand for targeted therapies in oncology and rare diseases necessitates AI-driven analytics to match patients with the most effective treatments, accelerating the adoption of personalized medicine solutions.
Restraint: Data privacy concerns and lack of interoperability
Significant challenges arise from data privacy concerns and the lack of standardized data interoperability. Healthcare data is highly sensitive, and navigating regulations like HIPAA and GDPR creates complexity for AI developers. Additionally, fragmented electronic health record (EHR) systems often store data in siloed, incompatible formats, hindering the creation of large, unified datasets required to train robust AI models. The 'black box' nature of some AI algorithms also poses a barrier to clinical adoption, as physicians often require explainable outputs to trust AI-driven recommendations for patient care, slowing integration into clinical workflows.
Opportunity: Integration with wearables and IoT devices
The integration of AI with wearable health monitoring devices and the Internet of Things (IoT) presents a significant growth opportunity. Continuous streams of real-world data from smartwatches and implantable sensors allow AI models to monitor patient health dynamically, predict adverse events, and adjust treatment plans in real-time. This capability is particularly valuable for managing chronic diseases like diabetes and cardiovascular conditions. Moreover, the expansion of telehealth and remote patient monitoring creates a fertile ground for AI-powered platforms that can deliver personalized care outside traditional hospital settings, improving accessibility and patient engagement.
Threat: Algorithmic bias and regulatory uncertainty
Algorithmic bias poses a critical threat to the equitable deployment of AI in personalized medicine. If AI models are trained predominantly on datasets from specific demographic groups, their predictive accuracy may be significantly lower for underrepresented populations. This can lead to misdiagnosis or ineffective treatment recommendations for minority groups, exacerbating existing healthcare disparities. Additionally, the rapid pace of AI development often outstrips the regulatory frameworks designed to ensure safety and efficacy, creating uncertainty for developers and potential risks for patients if unvalidated tools are adopted prematurely.
Covid-19 Impact
The pandemic acted as a powerful catalyst for AI adoption in personalized medicine. The urgent need for rapid vaccine development and repurposing of existing drugs saw AI used to analyze viral genomics and host responses at unprecedented speeds. Lockdowns accelerated the adoption of telemedicine and remote monitoring, driving demand for AI tools to manage patient data remotely. However, the crisis also overwhelmed healthcare systems, diverting resources from non-COVID research and delaying some clinical trials for AI-based diagnostics. Post-pandemic, there is a sustained focus on building resilient, AI-driven healthcare systems capable of rapid, personalized responses to future health crises.
The software segment is expected to be the largest during the forecast period
The software segment, particularly AI analytics platforms and clinical decision support systems (CDSS), is expected to account for the largest market share. This dominance is driven by the foundational role of software in processing complex genomic and clinical data to generate actionable insights. Hospitals and research institutes are heavily investing in these platforms to enhance diagnostic accuracy and streamline drug discovery. The scalability and continuous upgradability of cloud-based software solutions further solidify their market leadership, as they form the core infrastructure for any personalized medicine initiative.
The hardware segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the hardware segment is predicted to witness the highest growth rate, driven by the increasing need for high-performance computing (HPC) infrastructure. The immense computational power required to train deep learning models on genomic and imaging datasets is fueling demand for advanced processors and AI-enabled medical devices. Additionally, the proliferation of wearable health monitoring devices that generate personalized patient data is contributing to this rapid expansion. As AI algorithms become more complex, the demand for specialized hardware to support them will continue to accelerate.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, driven by substantial R&D investments, a strong presence of key technology players, and a sophisticated healthcare infrastructure. The United States, in particular, leads in the adoption of AI-driven genomic testing and digital therapeutics. Favorable reimbursement frameworks for personalized medicine and high healthcare expenditure support the integration of advanced AI tools into clinical practice, solidifying the region's dominant position.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rapid digitalization of healthcare systems, large patient populations generating vast datasets, and increasing government initiatives for precision medicine. Countries like China, Japan, and India are investing heavily in genomics research and AI infrastructure. The growing prevalence of chronic diseases and a burgeoning medical tourism sector are accelerating the adoption of advanced AI technologies to offer personalized and efficient care, driving significant market expansion.
Key players in the market
Some of the key players in AI in Personalized Medicine Market include NVIDIA Corporation, Google LLC, Microsoft Corporation, IBM Corporation, Illumina, Inc., GE HealthCare, Siemens Healthineers AG, Tempus AI, Exscientia plc, Insilico Medicine, BenevolentAI, PathAI, Inc., Guardant Health, Inc., Deep Genomics, and Paige AI, Inc.
Key Developments:
In March 2026, IBM and ETH Zurich announced a 10-year collaboration to advance the next generation of algorithms at the intersection of AI and quantum computing. This initiative represents the latest milestone in the long-standing collaboration between the two institutions, further strengthening a scientific exchange that has helped create the future of information technology.
In March 2026, NVIDIA and Marvell Technology, Inc. announced a strategic partnership to connect Marvell to the NVIDIA AI factory and AI-RAN ecosystem through NVIDIA NVLink Fusion™, offering customers building on NVIDIA architectures greater choice and flexibility in developing next-generation infrastructure. The companies will also collaborate on silicon photonics technology.
Components Covered:
All the customers of this report will be entitled to receive one of the following free customization options:
Market Dynamics:
Driver:
Exponential growth in genomic and multi-omics data
The exponential growth in genomic and multi-omics data is a primary driver for AI integration. As sequencing costs decline, the volume of genetic information available for analysis has surged. AI algorithms, particularly machine learning, are uniquely capable of processing these vast, complex datasets to identify disease markers and predict drug responses. This capability enables the shift from traditional trial-and-error medicine to precise therapeutic interventions. Furthermore, the increasing demand for targeted therapies in oncology and rare diseases necessitates AI-driven analytics to match patients with the most effective treatments, accelerating the adoption of personalized medicine solutions.
Restraint: Data privacy concerns and lack of interoperability
Significant challenges arise from data privacy concerns and the lack of standardized data interoperability. Healthcare data is highly sensitive, and navigating regulations like HIPAA and GDPR creates complexity for AI developers. Additionally, fragmented electronic health record (EHR) systems often store data in siloed, incompatible formats, hindering the creation of large, unified datasets required to train robust AI models. The 'black box' nature of some AI algorithms also poses a barrier to clinical adoption, as physicians often require explainable outputs to trust AI-driven recommendations for patient care, slowing integration into clinical workflows.
Opportunity: Integration with wearables and IoT devices
The integration of AI with wearable health monitoring devices and the Internet of Things (IoT) presents a significant growth opportunity. Continuous streams of real-world data from smartwatches and implantable sensors allow AI models to monitor patient health dynamically, predict adverse events, and adjust treatment plans in real-time. This capability is particularly valuable for managing chronic diseases like diabetes and cardiovascular conditions. Moreover, the expansion of telehealth and remote patient monitoring creates a fertile ground for AI-powered platforms that can deliver personalized care outside traditional hospital settings, improving accessibility and patient engagement.
Threat: Algorithmic bias and regulatory uncertainty
Algorithmic bias poses a critical threat to the equitable deployment of AI in personalized medicine. If AI models are trained predominantly on datasets from specific demographic groups, their predictive accuracy may be significantly lower for underrepresented populations. This can lead to misdiagnosis or ineffective treatment recommendations for minority groups, exacerbating existing healthcare disparities. Additionally, the rapid pace of AI development often outstrips the regulatory frameworks designed to ensure safety and efficacy, creating uncertainty for developers and potential risks for patients if unvalidated tools are adopted prematurely.
Covid-19 Impact
The pandemic acted as a powerful catalyst for AI adoption in personalized medicine. The urgent need for rapid vaccine development and repurposing of existing drugs saw AI used to analyze viral genomics and host responses at unprecedented speeds. Lockdowns accelerated the adoption of telemedicine and remote monitoring, driving demand for AI tools to manage patient data remotely. However, the crisis also overwhelmed healthcare systems, diverting resources from non-COVID research and delaying some clinical trials for AI-based diagnostics. Post-pandemic, there is a sustained focus on building resilient, AI-driven healthcare systems capable of rapid, personalized responses to future health crises.
The software segment is expected to be the largest during the forecast period
The software segment, particularly AI analytics platforms and clinical decision support systems (CDSS), is expected to account for the largest market share. This dominance is driven by the foundational role of software in processing complex genomic and clinical data to generate actionable insights. Hospitals and research institutes are heavily investing in these platforms to enhance diagnostic accuracy and streamline drug discovery. The scalability and continuous upgradability of cloud-based software solutions further solidify their market leadership, as they form the core infrastructure for any personalized medicine initiative.
The hardware segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the hardware segment is predicted to witness the highest growth rate, driven by the increasing need for high-performance computing (HPC) infrastructure. The immense computational power required to train deep learning models on genomic and imaging datasets is fueling demand for advanced processors and AI-enabled medical devices. Additionally, the proliferation of wearable health monitoring devices that generate personalized patient data is contributing to this rapid expansion. As AI algorithms become more complex, the demand for specialized hardware to support them will continue to accelerate.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, driven by substantial R&D investments, a strong presence of key technology players, and a sophisticated healthcare infrastructure. The United States, in particular, leads in the adoption of AI-driven genomic testing and digital therapeutics. Favorable reimbursement frameworks for personalized medicine and high healthcare expenditure support the integration of advanced AI tools into clinical practice, solidifying the region's dominant position.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rapid digitalization of healthcare systems, large patient populations generating vast datasets, and increasing government initiatives for precision medicine. Countries like China, Japan, and India are investing heavily in genomics research and AI infrastructure. The growing prevalence of chronic diseases and a burgeoning medical tourism sector are accelerating the adoption of advanced AI technologies to offer personalized and efficient care, driving significant market expansion.
Key players in the market
Some of the key players in AI in Personalized Medicine Market include NVIDIA Corporation, Google LLC, Microsoft Corporation, IBM Corporation, Illumina, Inc., GE HealthCare, Siemens Healthineers AG, Tempus AI, Exscientia plc, Insilico Medicine, BenevolentAI, PathAI, Inc., Guardant Health, Inc., Deep Genomics, and Paige AI, Inc.
Key Developments:
In March 2026, IBM and ETH Zurich announced a 10-year collaboration to advance the next generation of algorithms at the intersection of AI and quantum computing. This initiative represents the latest milestone in the long-standing collaboration between the two institutions, further strengthening a scientific exchange that has helped create the future of information technology.
In March 2026, NVIDIA and Marvell Technology, Inc. announced a strategic partnership to connect Marvell to the NVIDIA AI factory and AI-RAN ecosystem through NVIDIA NVLink Fusion™, offering customers building on NVIDIA architectures greater choice and flexibility in developing next-generation infrastructure. The companies will also collaborate on silicon photonics technology.
Components Covered:
- Software
- Hardware
- Services
- Machine Learning
- Natural Language Processing (NLP)
- Computer Vision
- Context-Aware AI Processing
- Expert Systems
- Oncology
- Cardiology
- Neurology
- Infectious Diseases
- Rare Diseases
- Respiratory Disorders
- Genomic Data
- Clinical Data
- Imaging Data
- Real-World Data (RWD)
- Patient-Generated Data
- Drug Discovery & Development
- Genomics & Multi-Omics Analysis
- Clinical Decision Support
- Personalized Treatment Planning
- Biomarker Discovery
- Patient Monitoring & Predictive Analytics
- Hospitals & Healthcare Providers
- Pharmaceutical & Biotechnology Companies
- Research Institutes & Academic Centers
- Diagnostic Laboratories
- Contract Research Organizations (CROs)
- Other End Users
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
- Rest of the World (RoW)
- Middle East
- Saudi Arabia
- United Arab Emirates
- Qatar
- Israel
- Rest of Middle East
- Africa
- South Africa
- Egypt
- Morocco
- Rest of Africa
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 EXECUTIVE SUMMARY
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY COMPONENT
5.1 Software
5.1.1 AI Analytics Platforms
5.1.2 Genomic Analysis Software
5.1.3 Clinical Decision Support Systems
5.1.4 Predictive Modeling Tools
5.2 Hardware
5.2.1 AI-Enabled Medical Devices
5.2.2 High-Performance Computing Infrastructure
5.2.3 Wearable Health Monitoring Devices
5.3 Services
5.3.1 Consulting Services
5.3.2 Integration & Deployment Services
5.3.3 Maintenance & Support Services
6 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY TECHNOLOGY
6.1 Machine Learning
6.1.1 Deep Learning
6.1.2 Neural Networks
6.1.3 Random Forest Algorithms
6.1.4 Support Vector Machines
6.2 Natural Language Processing (NLP)
6.2.1 Clinical Text Mining
6.2.2 Medical Entity Recognition
6.2.3 Sentiment and Outcome Analysis
6.3 Computer Vision
6.4 Context-Aware AI Processing
6.5 Expert Systems
6.5.1 Rule-Based Systems
6.5.2 Decision Trees
6.5.3 Bayesian Networks
7 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY THERAPEUTIC AREA
7.1 Oncology
7.2 Cardiology
7.3 Neurology
7.4 Infectious Diseases
7.5 Rare Diseases
7.6 Respiratory Disorders
8 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY DATA TYPE
8.1 Genomic Data
8.2 Clinical Data
8.3 Imaging Data
8.4 Real-World Data (RWD)
8.5 Patient-Generated Data
9 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY APPLICATION
9.1 Drug Discovery & Development
9.1.1 Target Identification
9.1.2 Molecular Modeling
9.1.3 Virtual Screening
9.2 Genomics & Multi-Omics Analysis
9.2.1 Genomics
9.2.2 Proteomics
9.2.3 Metabolomics
9.2.4 Pharmacogenomics
9.3 Clinical Decision Support
9.3.1 Diagnosis Support
9.3.2 Treatment Selection
9.3.3 Disease Risk Prediction
9.4 Personalized Treatment Planning
9.5 Biomarker Discovery
9.6 Patient Monitoring & Predictive Analytics
10 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY END USER
10.1 Hospitals & Healthcare Providers
10.2 Pharmaceutical & Biotechnology Companies
10.3 Research Institutes & Academic Centers
10.4 Diagnostic Laboratories
10.5 Contract Research Organizations (CROs)
10.6 Other End Users
11 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY GEOGRAPHY
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands
11.2.7 Belgium
11.2.8 Sweden
11.2.9 Switzerland
11.2.10 Poland
11.2.11 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Indonesia
11.3.7 Thailand
11.3.8 Malaysia
11.3.9 Singapore
11.3.10 Vietnam
11.3.11 Rest of Asia Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Colombia
11.4.4 Chile
11.4.5 Peru
11.4.6 Rest of South America
11.5 Rest of the World (RoW)
11.5.1 Middle East
11.5.1.1 Saudi Arabia
11.5.1.2 United Arab Emirates
11.5.1.3 Qatar
11.5.1.4 Israel
11.5.1.5 Rest of Middle East
11.5.2 Africa
11.5.2.1 South Africa
11.5.2.2 Egypt
11.5.2.3 Morocco
11.5.2.4 Rest of Africa
12 STRATEGIC MARKET INTELLIGENCE
12.1 Industry Value Network and Supply Chain Assessment
12.2 White-Space and Opportunity Mapping
12.3 Product Evolution and Market Life Cycle Analysis
12.4 Channel, Distributor, and Go-to-Market Assessment
13 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
13.1 Mergers and Acquisitions
13.2 Partnerships, Alliances, and Joint Ventures
13.3 New Product Launches and Certifications
13.4 Capacity Expansion and Investments
13.5 Other Strategic Initiatives
14 COMPANY PROFILES
14.1 NVIDIA Corporation
14.2 Google LLC
14.3 Microsoft Corporation
14.4 IBM Corporation
14.5 Illumina, Inc.
14.6 GE HealthCare
14.7 Siemens Healthineers AG
14.8 Tempus AI
14.9 Exscientia plc
14.10 Insilico Medicine
14.11 BenevolentAI
14.12 PathAI, Inc.
14.13 Guardant Health, Inc.
14.14 Deep Genomics
14.15 Paige AI, Inc.
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY COMPONENT
5.1 Software
5.1.1 AI Analytics Platforms
5.1.2 Genomic Analysis Software
5.1.3 Clinical Decision Support Systems
5.1.4 Predictive Modeling Tools
5.2 Hardware
5.2.1 AI-Enabled Medical Devices
5.2.2 High-Performance Computing Infrastructure
5.2.3 Wearable Health Monitoring Devices
5.3 Services
5.3.1 Consulting Services
5.3.2 Integration & Deployment Services
5.3.3 Maintenance & Support Services
6 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY TECHNOLOGY
6.1 Machine Learning
6.1.1 Deep Learning
6.1.2 Neural Networks
6.1.3 Random Forest Algorithms
6.1.4 Support Vector Machines
6.2 Natural Language Processing (NLP)
6.2.1 Clinical Text Mining
6.2.2 Medical Entity Recognition
6.2.3 Sentiment and Outcome Analysis
6.3 Computer Vision
6.4 Context-Aware AI Processing
6.5 Expert Systems
6.5.1 Rule-Based Systems
6.5.2 Decision Trees
6.5.3 Bayesian Networks
7 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY THERAPEUTIC AREA
7.1 Oncology
7.2 Cardiology
7.3 Neurology
7.4 Infectious Diseases
7.5 Rare Diseases
7.6 Respiratory Disorders
8 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY DATA TYPE
8.1 Genomic Data
8.2 Clinical Data
8.3 Imaging Data
8.4 Real-World Data (RWD)
8.5 Patient-Generated Data
9 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY APPLICATION
9.1 Drug Discovery & Development
9.1.1 Target Identification
9.1.2 Molecular Modeling
9.1.3 Virtual Screening
9.2 Genomics & Multi-Omics Analysis
9.2.1 Genomics
9.2.2 Proteomics
9.2.3 Metabolomics
9.2.4 Pharmacogenomics
9.3 Clinical Decision Support
9.3.1 Diagnosis Support
9.3.2 Treatment Selection
9.3.3 Disease Risk Prediction
9.4 Personalized Treatment Planning
9.5 Biomarker Discovery
9.6 Patient Monitoring & Predictive Analytics
10 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY END USER
10.1 Hospitals & Healthcare Providers
10.2 Pharmaceutical & Biotechnology Companies
10.3 Research Institutes & Academic Centers
10.4 Diagnostic Laboratories
10.5 Contract Research Organizations (CROs)
10.6 Other End Users
11 GLOBAL AI IN PERSONALIZED MEDICINE MARKET, BY GEOGRAPHY
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands
11.2.7 Belgium
11.2.8 Sweden
11.2.9 Switzerland
11.2.10 Poland
11.2.11 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Indonesia
11.3.7 Thailand
11.3.8 Malaysia
11.3.9 Singapore
11.3.10 Vietnam
11.3.11 Rest of Asia Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Colombia
11.4.4 Chile
11.4.5 Peru
11.4.6 Rest of South America
11.5 Rest of the World (RoW)
11.5.1 Middle East
11.5.1.1 Saudi Arabia
11.5.1.2 United Arab Emirates
11.5.1.3 Qatar
11.5.1.4 Israel
11.5.1.5 Rest of Middle East
11.5.2 Africa
11.5.2.1 South Africa
11.5.2.2 Egypt
11.5.2.3 Morocco
11.5.2.4 Rest of Africa
12 STRATEGIC MARKET INTELLIGENCE
12.1 Industry Value Network and Supply Chain Assessment
12.2 White-Space and Opportunity Mapping
12.3 Product Evolution and Market Life Cycle Analysis
12.4 Channel, Distributor, and Go-to-Market Assessment
13 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
13.1 Mergers and Acquisitions
13.2 Partnerships, Alliances, and Joint Ventures
13.3 New Product Launches and Certifications
13.4 Capacity Expansion and Investments
13.5 Other Strategic Initiatives
14 COMPANY PROFILES
14.1 NVIDIA Corporation
14.2 Google LLC
14.3 Microsoft Corporation
14.4 IBM Corporation
14.5 Illumina, Inc.
14.6 GE HealthCare
14.7 Siemens Healthineers AG
14.8 Tempus AI
14.9 Exscientia plc
14.10 Insilico Medicine
14.11 BenevolentAI
14.12 PathAI, Inc.
14.13 Guardant Health, Inc.
14.14 Deep Genomics
14.15 Paige AI, Inc.
LIST OF TABLES
Table 1 Global AI in Personalized Medicine Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global AI in Personalized Medicine Market Outlook, By Component (2023-2034) ($MN)
Table 3 Global AI in Personalized Medicine Market Outlook, By Software (2023-2034) ($MN)
Table 4 Global AI in Personalized Medicine Market Outlook, By AI Analytics Platforms (2023-2034) ($MN)
Table 5 Global AI in Personalized Medicine Market Outlook, By Genomic Analysis Software (2023-2034) ($MN)
Table 6 Global AI in Personalized Medicine Market Outlook, By Clinical Decision Support Systems (2023-2034) ($MN)
Table 7 Global AI in Personalized Medicine Market Outlook, By Predictive Modeling Tools (2023-2034) ($MN)
Table 8 Global AI in Personalized Medicine Market Outlook, By Hardware (2023-2034) ($MN)
Table 9 Global AI in Personalized Medicine Market Outlook, By AI-Enabled Medical Devices (2023-2034) ($MN)
Table 10 Global AI in Personalized Medicine Market Outlook, By High-Performance Computing Infrastructure (2023-2034) ($MN)
Table 11 Global AI in Personalized Medicine Market Outlook, By Wearable Health Monitoring Devices (2023-2034) ($MN)
Table 12 Global AI in Personalized Medicine Market Outlook, By Services (2023-2034) ($MN)
Table 13 Global AI in Personalized Medicine Market Outlook, By Consulting Services (2023-2034) ($MN)
Table 14 Global AI in Personalized Medicine Market Outlook, By Integration & Deployment Services (2023-2034) ($MN)
Table 15 Global AI in Personalized Medicine Market Outlook, By Maintenance & Support Services (2023-2034) ($MN)
Table 16 Global AI in Personalized Medicine Market Outlook, By Technology (2023-2034) ($MN)
Table 17 Global AI in Personalized Medicine Market Outlook, By Machine Learning (2023-2034) ($MN)
Table 18 Global AI in Personalized Medicine Market Outlook, By Deep Learning (2023-2034) ($MN)
Table 19 Global AI in Personalized Medicine Market Outlook, By Neural Networks (2023-2034) ($MN)
Table 20 Global AI in Personalized Medicine Market Outlook, By Random Forest Algorithms (2023-2034) ($MN)
Table 21 Global AI in Personalized Medicine Market Outlook, By Support Vector Machines (2023-2034) ($MN)
Table 22 Global AI in Personalized Medicine Market Outlook, By Natural Language Processing (NLP) (2023-2034) ($MN)
Table 23 Global AI in Personalized Medicine Market Outlook, By Clinical Text Mining (2023-2034) ($MN)
Table 24 Global AI in Personalized Medicine Market Outlook, By Medical Entity Recognition (2023-2034) ($MN)
Table 25 Global AI in Personalized Medicine Market Outlook, By Sentiment and Outcome Analysis (2023-2034) ($MN)
Table 26 Global AI in Personalized Medicine Market Outlook, By Computer Vision (2023-2034) ($MN)
Table 27 Global AI in Personalized Medicine Market Outlook, By Context-Aware AI Processing (2023-2034) ($MN)
Table 28 Global AI in Personalized Medicine Market Outlook, By Expert Systems (2023-2034) ($MN)
Table 29 Global AI in Personalized Medicine Market Outlook, By Rule-Based Systems (2023-2034) ($MN)
Table 30 Global AI in Personalized Medicine Market Outlook, By Decision Trees (2023-2034) ($MN)
Table 31 Global AI in Personalized Medicine Market Outlook, By Bayesian Networks (2023-2034) ($MN)
Table 32 Global AI in Personalized Medicine Market Outlook, By Therapeutic Area (2023-2034) ($MN)
Table 33 Global AI in Personalized Medicine Market Outlook, By Oncology (2023-2034) ($MN)
Table 34 Global AI in Personalized Medicine Market Outlook, By Cardiology (2023-2034) ($MN)
Table 35 Global AI in Personalized Medicine Market Outlook, By Neurology (2023-2034) ($MN)
Table 36 Global AI in Personalized Medicine Market Outlook, By Infectious Diseases (2023-2034) ($MN)
Table 37 Global AI in Personalized Medicine Market Outlook, By Rare Diseases (2023-2034) ($MN)
Table 38 Global AI in Personalized Medicine Market Outlook, By Respiratory Disorders (2023-2034) ($MN)
Table 39 Global AI in Personalized Medicine Market Outlook, By Data Type (2023-2034) ($MN)
Table 40 Global AI in Personalized Medicine Market Outlook, By Genomic Data (2023-2034) ($MN)
Table 41 Global AI in Personalized Medicine Market Outlook, By Clinical Data (2023-2034) ($MN)
Table 42 Global AI in Personalized Medicine Market Outlook, By Imaging Data (2023-2034) ($MN)
Table 43 Global AI in Personalized Medicine Market Outlook, By Real-World Data (RWD) (2023-2034) ($MN)
Table 44 Global AI in Personalized Medicine Market Outlook, By Patient-Generated Data (2023-2034) ($MN)
Table 45 Global AI in Personalized Medicine Market Outlook, By Application (2023-2034) ($MN)
Table 46 Global AI in Personalized Medicine Market Outlook, By Drug Discovery & Development (2023-2034) ($MN)
Table 47 Global AI in Personalized Medicine Market Outlook, By Target Identification (2023-2034) ($MN)
Table 48 Global AI in Personalized Medicine Market Outlook, By Molecular Modeling (2023-2034) ($MN)
Table 49 Global AI in Personalized Medicine Market Outlook, By Virtual Screening (2023-2034) ($MN)
Table 50 Global AI in Personalized Medicine Market Outlook, By Genomics & Multi-Omics Analysis (2023-2034) ($MN)
Table 51 Global AI in Personalized Medicine Market Outlook, By Genomics (2023-2034) ($MN)
Table 52 Global AI in Personalized Medicine Market Outlook, By Proteomics (2023-2034) ($MN)
Table 53 Global AI in Personalized Medicine Market Outlook, By Metabolomics (2023-2034) ($MN)
Table 54 Global AI in Personalized Medicine Market Outlook, By Pharmacogenomics (2023-2034) ($MN)
Table 55 Global AI in Personalized Medicine Market Outlook, By Clinical Decision Support (2023-2034) ($MN)
Table 56 Global AI in Personalized Medicine Market Outlook, By Diagnosis Support (2023-2034) ($MN)
Table 57 Global AI in Personalized Medicine Market Outlook, By Treatment Selection (2023-2034) ($MN)
Table 58 Global AI in Personalized Medicine Market Outlook, By Disease Risk Prediction (2023-2034) ($MN)
Table 59 Global AI in Personalized Medicine Market Outlook, By Personalized Treatment Planning (2023-2034) ($MN)
Table 60 Global AI in Personalized Medicine Market Outlook, By Biomarker Discovery (2023-2034) ($MN)
Table 61 Global AI in Personalized Medicine Market Outlook, By Patient Monitoring & Predictive Analytics (2023-2034) ($MN)
Table 62 Global AI in Personalized Medicine Market Outlook, By End User (2023-2034) ($MN)
Table 63 Global AI in Personalized Medicine Market Outlook, By Hospitals & Healthcare Providers (2023-2034) ($MN)
Table 64 Global AI in Personalized Medicine Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
Table 65 Global AI in Personalized Medicine Market Outlook, By Research Institutes & Academic Centers (2023-2034) ($MN)
Table 66 Global AI in Personalized Medicine Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
Table 67 Global AI in Personalized Medicine Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
Table 68 Global AI in Personalized Medicine Market Outlook, By Other End Users (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.
Table 1 Global AI in Personalized Medicine Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global AI in Personalized Medicine Market Outlook, By Component (2023-2034) ($MN)
Table 3 Global AI in Personalized Medicine Market Outlook, By Software (2023-2034) ($MN)
Table 4 Global AI in Personalized Medicine Market Outlook, By AI Analytics Platforms (2023-2034) ($MN)
Table 5 Global AI in Personalized Medicine Market Outlook, By Genomic Analysis Software (2023-2034) ($MN)
Table 6 Global AI in Personalized Medicine Market Outlook, By Clinical Decision Support Systems (2023-2034) ($MN)
Table 7 Global AI in Personalized Medicine Market Outlook, By Predictive Modeling Tools (2023-2034) ($MN)
Table 8 Global AI in Personalized Medicine Market Outlook, By Hardware (2023-2034) ($MN)
Table 9 Global AI in Personalized Medicine Market Outlook, By AI-Enabled Medical Devices (2023-2034) ($MN)
Table 10 Global AI in Personalized Medicine Market Outlook, By High-Performance Computing Infrastructure (2023-2034) ($MN)
Table 11 Global AI in Personalized Medicine Market Outlook, By Wearable Health Monitoring Devices (2023-2034) ($MN)
Table 12 Global AI in Personalized Medicine Market Outlook, By Services (2023-2034) ($MN)
Table 13 Global AI in Personalized Medicine Market Outlook, By Consulting Services (2023-2034) ($MN)
Table 14 Global AI in Personalized Medicine Market Outlook, By Integration & Deployment Services (2023-2034) ($MN)
Table 15 Global AI in Personalized Medicine Market Outlook, By Maintenance & Support Services (2023-2034) ($MN)
Table 16 Global AI in Personalized Medicine Market Outlook, By Technology (2023-2034) ($MN)
Table 17 Global AI in Personalized Medicine Market Outlook, By Machine Learning (2023-2034) ($MN)
Table 18 Global AI in Personalized Medicine Market Outlook, By Deep Learning (2023-2034) ($MN)
Table 19 Global AI in Personalized Medicine Market Outlook, By Neural Networks (2023-2034) ($MN)
Table 20 Global AI in Personalized Medicine Market Outlook, By Random Forest Algorithms (2023-2034) ($MN)
Table 21 Global AI in Personalized Medicine Market Outlook, By Support Vector Machines (2023-2034) ($MN)
Table 22 Global AI in Personalized Medicine Market Outlook, By Natural Language Processing (NLP) (2023-2034) ($MN)
Table 23 Global AI in Personalized Medicine Market Outlook, By Clinical Text Mining (2023-2034) ($MN)
Table 24 Global AI in Personalized Medicine Market Outlook, By Medical Entity Recognition (2023-2034) ($MN)
Table 25 Global AI in Personalized Medicine Market Outlook, By Sentiment and Outcome Analysis (2023-2034) ($MN)
Table 26 Global AI in Personalized Medicine Market Outlook, By Computer Vision (2023-2034) ($MN)
Table 27 Global AI in Personalized Medicine Market Outlook, By Context-Aware AI Processing (2023-2034) ($MN)
Table 28 Global AI in Personalized Medicine Market Outlook, By Expert Systems (2023-2034) ($MN)
Table 29 Global AI in Personalized Medicine Market Outlook, By Rule-Based Systems (2023-2034) ($MN)
Table 30 Global AI in Personalized Medicine Market Outlook, By Decision Trees (2023-2034) ($MN)
Table 31 Global AI in Personalized Medicine Market Outlook, By Bayesian Networks (2023-2034) ($MN)
Table 32 Global AI in Personalized Medicine Market Outlook, By Therapeutic Area (2023-2034) ($MN)
Table 33 Global AI in Personalized Medicine Market Outlook, By Oncology (2023-2034) ($MN)
Table 34 Global AI in Personalized Medicine Market Outlook, By Cardiology (2023-2034) ($MN)
Table 35 Global AI in Personalized Medicine Market Outlook, By Neurology (2023-2034) ($MN)
Table 36 Global AI in Personalized Medicine Market Outlook, By Infectious Diseases (2023-2034) ($MN)
Table 37 Global AI in Personalized Medicine Market Outlook, By Rare Diseases (2023-2034) ($MN)
Table 38 Global AI in Personalized Medicine Market Outlook, By Respiratory Disorders (2023-2034) ($MN)
Table 39 Global AI in Personalized Medicine Market Outlook, By Data Type (2023-2034) ($MN)
Table 40 Global AI in Personalized Medicine Market Outlook, By Genomic Data (2023-2034) ($MN)
Table 41 Global AI in Personalized Medicine Market Outlook, By Clinical Data (2023-2034) ($MN)
Table 42 Global AI in Personalized Medicine Market Outlook, By Imaging Data (2023-2034) ($MN)
Table 43 Global AI in Personalized Medicine Market Outlook, By Real-World Data (RWD) (2023-2034) ($MN)
Table 44 Global AI in Personalized Medicine Market Outlook, By Patient-Generated Data (2023-2034) ($MN)
Table 45 Global AI in Personalized Medicine Market Outlook, By Application (2023-2034) ($MN)
Table 46 Global AI in Personalized Medicine Market Outlook, By Drug Discovery & Development (2023-2034) ($MN)
Table 47 Global AI in Personalized Medicine Market Outlook, By Target Identification (2023-2034) ($MN)
Table 48 Global AI in Personalized Medicine Market Outlook, By Molecular Modeling (2023-2034) ($MN)
Table 49 Global AI in Personalized Medicine Market Outlook, By Virtual Screening (2023-2034) ($MN)
Table 50 Global AI in Personalized Medicine Market Outlook, By Genomics & Multi-Omics Analysis (2023-2034) ($MN)
Table 51 Global AI in Personalized Medicine Market Outlook, By Genomics (2023-2034) ($MN)
Table 52 Global AI in Personalized Medicine Market Outlook, By Proteomics (2023-2034) ($MN)
Table 53 Global AI in Personalized Medicine Market Outlook, By Metabolomics (2023-2034) ($MN)
Table 54 Global AI in Personalized Medicine Market Outlook, By Pharmacogenomics (2023-2034) ($MN)
Table 55 Global AI in Personalized Medicine Market Outlook, By Clinical Decision Support (2023-2034) ($MN)
Table 56 Global AI in Personalized Medicine Market Outlook, By Diagnosis Support (2023-2034) ($MN)
Table 57 Global AI in Personalized Medicine Market Outlook, By Treatment Selection (2023-2034) ($MN)
Table 58 Global AI in Personalized Medicine Market Outlook, By Disease Risk Prediction (2023-2034) ($MN)
Table 59 Global AI in Personalized Medicine Market Outlook, By Personalized Treatment Planning (2023-2034) ($MN)
Table 60 Global AI in Personalized Medicine Market Outlook, By Biomarker Discovery (2023-2034) ($MN)
Table 61 Global AI in Personalized Medicine Market Outlook, By Patient Monitoring & Predictive Analytics (2023-2034) ($MN)
Table 62 Global AI in Personalized Medicine Market Outlook, By End User (2023-2034) ($MN)
Table 63 Global AI in Personalized Medicine Market Outlook, By Hospitals & Healthcare Providers (2023-2034) ($MN)
Table 64 Global AI in Personalized Medicine Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
Table 65 Global AI in Personalized Medicine Market Outlook, By Research Institutes & Academic Centers (2023-2034) ($MN)
Table 66 Global AI in Personalized Medicine Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
Table 67 Global AI in Personalized Medicine Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
Table 68 Global AI in Personalized Medicine Market Outlook, By Other End Users (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.
